Literature DB >> 17598582

Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma.

Jorge L Alio1, Silvia Pastor, Jose Ruiz-Colecha, Alejandra Rodriguez, Alberto Artola.   

Abstract

PURPOSE: To ascertain the usefulness of platelet-rich plasma in the treatment of patients suffering from symptomatic ocular surface syndrome following LASIK.
METHODS: Twenty-six eyes (9 women and 4 men) affected by symptomatic ocular surface syndrome were treated with topical eye drops of autologous platelet-rich plasma and results were reported at 4 weeks. Topical platelet-rich plasma was prepared from total blood and enriched in platelets by centrifugation.
RESULTS: Eighty-five percent of patients experienced significant improvement of symptoms; best spectacle-corrected visual acuity increased 1 to 2 lines in 54%; fluorescein staining analysis showed a 69% full fluorescein disappearance; and tear break-up time increased > 2 seconds in 46%. Only one patient developed intolerance to platelet-rich plasma after 4 weeks.
CONCLUSIONS: Autologous platelet-rich plasma was effective in the treatment of patients with ocular surface syndrome following LASIK, with symptoms generally relieved and a positive effect on punctate keratitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17598582     DOI: 10.3928/1081-597X-20070601-13

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  15 in total

1.  Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis.

Authors:  Kyoung Min Kim; Yong-Tae Shin; Hong Kyun Kim
Journal:  Jpn J Ophthalmol       Date:  2012-09-13       Impact factor: 2.447

Review 2.  Progress in corneal wound healing.

Authors:  Alexander V Ljubimov; Mehrnoosh Saghizadeh
Journal:  Prog Retin Eye Res       Date:  2015-07-18       Impact factor: 21.198

3.  Autologous Platelet-Rich Plasma Drops for Evaporative Dry Eye Disease from Meibomian Gland Dysfunction: A Pilot Study.

Authors:  Fahmeeda Murtaza; Dana Toameh; Hannah H Chiu; Eric S Tam; Sohel Somani
Journal:  Clin Ophthalmol       Date:  2022-07-06

4.  Effects of subtenon-injected autologous platelet-rich plasma on visual functions in eyes with retinitis pigmentosa: preliminary clinical results.

Authors:  Umut Arslan; Emin Özmert; Sibel Demirel; Firdevs Örnek; Figen Şermet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-15       Impact factor: 3.117

Review 5.  [Autologous serum and alternative blood products for the treatment of ocular surface disorders].

Authors:  G Geerling; J D Unterlauft; K Kasper; S Schrader; A Opitz; D Hartwig
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059

6.  Autologous Platelet-rich Plasma Eye Drops in the Treatment of Recurrent Corneal Erosions.

Authors:  Jun Hun Lee; Myung Jun Kim; Sang Won Ha; Hong Kyun Kim
Journal:  Korean J Ophthalmol       Date:  2016-03-25

Review 7.  Solid Platelet Rich Plasma in Corneal Surgery.

Authors:  Francisco Arnalich; Alejandra E Rodriguez; Alvaro Luque-Rio; Jorge L Alio
Journal:  Ophthalmol Ther       Date:  2016-05-14

8.  Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study.

Authors:  Jorge L Alio; Alejandra E Rodriguez; Renan Ferreira-Oliveira; Dominika Wróbel-Dudzińska; Ahmed A Abdelghany
Journal:  Ophthalmol Ther       Date:  2017-08-08

9.  Autologous Platelet-Rich Plasma Eye Drops for the Treatment of Post-LASIK Chronic Ocular Surface Syndrome.

Authors:  Jorge L Alio; Alejandra E Rodriguez; Ahmed A Abdelghany; Renan F Oliveira
Journal:  J Ophthalmol       Date:  2017-12-12       Impact factor: 1.909

10.  Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma.

Authors:  Ronald M Sánchez-Avila; Jesus Merayo-Lloves; Maria Laura Fernández; Luis Alberto Rodríguez-Gutiérrez; Pedro Pablo Rodríguez-Calvo; Andres Fernández-Vega Cueto; Francisco Muruzabal; Gorka Orive; Eduardo Anitua
Journal:  Int Med Case Rep J       Date:  2018-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.